Kisspeptin and alarelin for fertility on TRT: what the evidence actually shows

What did @sroka.dietcoach actually say?

The caption is doing most of the heavy lifting here. The creator claims that kisspeptin and alarelin are two peptides that "may support fertility" in the context of testosterone replacement therapy (TRT) and cycling. The caption goes on to describe kisspeptin as a "key regulator of the hypothalamic-pituitary-gonadal axis" that stimulates LH and FSH secretion. The spoken transcript, unfortunately, was incoherent and provided no usable claims, so this fact-check is based entirely on the written caption and the hashtags used (#kisspeptin, #alarelin, #płodność, #trt).

The framing, at least in the caption, is relatively measured. "May support" is not the same as "will restore." That said, presenting two peptides as a fertility solution for TRT users to an audience of 8,600 viewers, without mentioning regulatory status, clinical availability, or meaningful safety caveats, is a choice that deserves scrutiny.

Does the science back this up?

On kisspeptin, yes, partially. On alarelin, the evidence is thinner and more context-dependent than the caption implies.

Kisspeptin's role in the HPG axis is well-documented. It acts on GnRH neurons in the hypothalamus, triggering a downstream cascade that includes LH and FSH release. Dhillo et al. (2005, Journal of Clinical Endocrinology and Metabolism) demonstrated that IV kisspeptin-54 significantly elevated LH in healthy men. Later work by Jayasena et al. (2014, Clinical Endocrinology) showed kisspeptin administration could stimulate gonadotropins in men with hypogonadotropic hypogonadism. These are real findings from real trials.

Alarelin is a synthetic GnRH agonist. Used in pulsatile fashion, it can stimulate LH and FSH. Used continuously, it paradoxically suppresses them, which is how GnRH agonists are used in prostate cancer therapy. That distinction is absent from the caption, and its omission matters enormously for a TRT audience.

What did they get wrong (or right)?

Credit where it is due: describing kisspeptin as a regulator of the HPG axis that stimulates LH and FSH is accurate. That mechanistic description aligns with peer-reviewed literature and is not oversimplified to the point of being misleading.

What is missing, and what constitutes a meaningful gap, is any acknowledgment that alarelin's effect on fertility is highly dependent on dosing protocol. Continuous GnRH agonist exposure causes receptor downregulation and suppresses the very hormones the creator implies it stimulates. Karten and Rivier (1986, Neuroendocrinology) established this desensitization mechanism decades ago. A bodybuilder using alarelin incorrectly based on this video could make their suppression significantly worse, not better.

There is also no mention that neither kisspeptin nor alarelin is approved by the FDA or EMA for fertility indications in men on TRT. These are investigational or off-label compounds. Presenting them as a practical fertility support strategy without that context is incomplete at best.

What should you actually know?

If you are on TRT and concerned about fertility, the compounds with the most clinical use in this context are hCG (human chorionic gonadotropin) and, in some protocols, selective estrogen receptor modulators like clomiphene. These are not perfect, but they have more data behind them in men than either kisspeptin or alarelin currently do.

Kisspeptin research in humans is genuinely interesting and ongoing. A 2023 review by Abbara et al. in Nature Reviews Endocrinology summarizes its therapeutic potential and notes that trials in both male and female hypogonadism are expanding. But "potential" and "clinical standard of care" are not the same thing.

Alarelin is even less established in Western clinical practice. Most alarelin data comes from Chinese clinical trials, largely in female infertility contexts. The evidence base for its use in TRT-related male fertility is, to be direct, not there yet in any meaningful published form.

Anyone considering these peptides should do so only under physician supervision with baseline bloodwork, and should understand that the regulatory and safety landscape for compounded peptides is not equivalent to approved pharmaceuticals.